For the quarter ending 2025-03-31, CLCS had -$73,391 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-03-31 | 2024-12-31 |
|---|---|---|
| Net loss | -1,481,851 | -4,512,642 |
| Gain on extinguishment of note payable | - | 17,893 |
| Interest expense - amortization of debt discount-Nonrelated Party | 6,686 | 156,221 |
| Interest expense - amortization of debt discount-Related Party | 79,951 | 153,693 |
| Change in fair value of derivative liabilities - related party-Nonrelated Party | - | 353,174 |
| Change in fair value of derivative liabilities - related party-Related Party | - | 44,835 |
| Change in fair value of derivative and warrant liabilities | 30,610 | - |
| Non-cash interest expense - warrants | 32,992 | 135,924 |
| Warrant modification expense | 17,200 | 1,100 |
| Stock-based compensation-Common Stock | - | 254,214 |
| Stock-based compensation-Warrant | 3,875 | 34,210 |
| Stock-based compensation-Options | 100,600 | - |
| Prepaid expenses | -80,375 | -321,500 |
| Prepaid expenses - research and development | 209,427 | - |
| Other current assets | 285 | -11,099 |
| Accounts payable | 40,494 | 421,677 |
| Accrued expenses-Nonrelated Party | 326,196 | -109,694 |
| Accrued expenses-Related Party | 14,500 | 58,000 |
| Accrued interest-Nonrelated Party | 194,920 | 181,956 |
| Accrued interest-Related Party | 199,323 | 729,352 |
| Accrued compensation | 24,670 | 166,978 |
| Net cash used in operating activities | -600,391 | -2,684,162 |
| Proceeds from issuance of common stock and warrants | - | 640,626 |
| Proceeds from issuance of series b convertible preferred stock and warrants | 25,000 | 1,151,000 |
| Proceeds from subscription receivable-Nonrelated Party | 50,000 | - |
| Proceeds from issuance of common stock-Nonrelated Party | 150,000 | - |
| Proceeds from issuance of convertible notes payable-Related Party | - | 146,672 |
| Proceeds from issuance of convertible notes payable-Nonrelated Party | 56,000 | - |
| Proceeds from issuance of notes payable-Nonrelated Party | - | 449,965 |
| Payment of debt issuance costs | 6,000 | - |
| Proceeds from issuance of notes payable - related party-Related Party | 327,000 | 250,000 |
| Proceeds from advances payable-Nonrelated Party | - | 59,375 |
| Proceeds from advances payable-Related Party | - | 100,000 |
| Repayment of notes payable-Nonrelated Party | - | 6,250 |
| Repayment of notes payable-Related Party | - | 6,250 |
| Repayment of financing liability | - | 48,548 |
| Repayment of convertible notes payable | 75,000 | - |
| Net cash provided by financing activities | 527,000 | 2,736,590 |
| Net decrease in cash | -73,391 | 52,428 |
| Cash - beginning of period | 74,631 | 22,203 |
| Cash - end of period | 1,240 | 74,631 |
Cell Source, Inc. (CLCS)
Cell Source, Inc. (CLCS)